According to these findings, we established a therapeutic strategy for breast cancer utilizing the tumour-suppressive activity of PHB2 upon its release from BIG3 via the dominant negative peptide ERAP, which targets the BIG3-PHB2 interaction10. Here, PHB2 is linked to breast cancer.